Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study

JM Michot; R Bouabdallah; U Vitolo; Jeanette Doorduijn; G Salles; A Chiappella; PL Zinzani; F Bijou; MJ Kersten; R Sarmiento; S Mosulen; C Mendez; S Uttamsingh; M Pourdehnad; K Hege; TL Chen; C Klein; PR Hagner; Z Nikolova; V Ribrag

doi:10.1016/s2352-3026(20)30208-8

Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study

JM Michot, R Bouabdallah, U Vitolo, Jeanette Doorduijn, G Salles, A Chiappella, PL Zinzani, F Bijou, MJ Kersten, R Sarmiento, S Mosulen, C Mendez, S Uttamsingh, M Pourdehnad, K Hege, TL Chen, C Klein, PR Hagner, Z Nikolova, V Ribrag

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

17 Citations (Scopus)

Original language	English
Pages (from-to)	E649-E659
Journal	Lancet Haematology
Volume	7
Issue number	9
DOIs	https://doi.org/10.1016/s2352-3026(20)30208-8
Publication status	Published - 2020

Access to Document

10.1016/s2352-3026(20)30208-8

Cite this

Michot, JM., Bouabdallah, R., Vitolo, U., Doorduijn, J., Salles, G., Chiappella, A., Zinzani, PL., Bijou, F., Kersten, MJ., Sarmiento, R., Mosulen, S., Mendez, C., Uttamsingh, S., Pourdehnad, M., Hege, K., Chen, TL., Klein, C., Hagner, PR., Nikolova, Z., & Ribrag, V. (2020). Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. Lancet Haematology, 7(9), E649-E659. https://doi.org/10.1016/s2352-3026(20)30208-8

@article{4ff88272557a4c2dab9ce272dad8b51c,

title = "Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study",

author = "JM Michot and R Bouabdallah and U Vitolo and Jeanette Doorduijn and G Salles and A Chiappella and PL Zinzani and F Bijou and MJ Kersten and R Sarmiento and S Mosulen and C Mendez and S Uttamsingh and M Pourdehnad and K Hege and TL Chen and C Klein and PR Hagner and Z Nikolova and V Ribrag",

year = "2020",

doi = "10.1016/s2352-3026(20)30208-8",

language = "English",

volume = "7",

pages = "E649--E659",

journal = "Lancet Haematology",

issn = "2352-3026",

publisher = "Lancet Publishing Group",

number = "9",

}

Michot, JM, Bouabdallah, R, Vitolo, U, Doorduijn, J, Salles, G, Chiappella, A, Zinzani, PL, Bijou, F, Kersten, MJ, Sarmiento, R, Mosulen, S, Mendez, C, Uttamsingh, S, Pourdehnad, M, Hege, K, Chen, TL, Klein, C, Hagner, PR, Nikolova, Z & Ribrag, V 2020, 'Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study', Lancet Haematology, vol. 7, no. 9, pp. E649-E659. https://doi.org/10.1016/s2352-3026(20)30208-8

TY - JOUR

T1 - Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study

AU - Michot, JM

AU - Bouabdallah, R

AU - Vitolo, U

AU - Doorduijn, Jeanette

AU - Salles, G

AU - Chiappella, A

AU - Zinzani, PL

AU - Bijou, F

AU - Kersten, MJ

AU - Sarmiento, R

AU - Mosulen, S

AU - Mendez, C

AU - Uttamsingh, S

AU - Pourdehnad, M

AU - Hege, K

AU - Chen, TL

AU - Klein, C

AU - Hagner, PR

AU - Nikolova, Z

AU - Ribrag, V

PY - 2020

Y1 - 2020

U2 - 10.1016/s2352-3026(20)30208-8

DO - 10.1016/s2352-3026(20)30208-8

M3 - Article

SN - 2352-3026

VL - 7

SP - E649-E659

JO - Lancet Haematology

JF - Lancet Haematology

IS - 9

ER -